Preoperative Combined Radiation and Chemotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-03-31

Study Completion Date

2004-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is no established standard preoperative treatment in rectal cancer. Two large randomized studies in North America closed from lack of accrual; therefore the only method of assessing preoperative treatment in rectal cancer is from Phase II studies. This study builds on the experience at PMH gained in two previous studies which demonstrated a lower than expected toxicity with concurrent 5FU infusion and external radiotherapy. The current standard at PMH is preoperative radiation, 46Gy in 23 fractions with concurrent 5FU infusion 225mg/m2. An increase of radiation dose and consequent increase in chemotherapy may improve the response rate, but may also increase toxicity. It is proposed to increase the dose of radiotherapy to 50Gy in 25 fractions with concurrent chemotherapy and measure acute toxicity and complete remission rate.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MRI for Tumor During Chemoradiation for Anal Canal and Perianal Cancer

NCT01053923

Anal Cancer Patients Perianal Patients

WITHDRAWN

Radiation Therapy Plus Chemotherapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum

NCT00006366

Colorectal Cancer

COMPLETED PHASE2

Preoperative Chemoradiotherapy With Capecitabine Plus Irinotecan in Rectal Cancer

NCT00506623

Rectal Neoplasm Neoadjuvant Therapy

UNKNOWN PHASE2

No Surgery Trial / Two Dose-escalation Strategies

NCT03051464

Stage II Rectal Cancer

RECRUITING PHASE2/PHASE3

Non-operative Management for Locally Advanced Rectal Cancer

NCT03179540

Rectal Neoplasms

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rectal Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Combined Radiation and Chemotherapy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Biopsy proven adenocarcinoma of the rectum
* Performance status \<2 (ECOG, appendix II)
* Clinical Stage T2 N1-2, T3-4 NO-2, without evidence of distant metastasis